Revenio stock analysis
Revenio (0KFH) Share Price & Analysis
0KFH Stock Chart & Stats
- Day’s Range
- EUR 10.00 - EUR 10.45
- 52-Week Range
- EUR 9.95 - EUR 20.27
- Previous Close
- EUR 10.00
- Volume
- N/A
- Average Volume (3M)
- 939
- Market Cap
- EUR 389.62M
- Enterprise Value
- EUR 546.60M
- Total Cash (Recent Filing)
- EUR 22.20M
- Total Debt (Recent Filing)
- EUR 2.40M
- Price to Earnings (P/E)
- 21.0
- Beta
- 0.65
- Next Earnings
- Feb 11, 2027 (Est.)
- EPS Estimate
- 0.15
- Last Dividend Ex-Date
- Apr 16, 2026
- Dividend Yield
- 5.27%
Revenio News
0KFH FAQ
What was Revenio’s price range in the past 12 months?
What is Revenio’s market cap?
When is Revenio’s upcoming earnings report date?
How were Revenio’s earnings last quarter?
Is Revenio overvalued?
Does Revenio pay dividends?
What is Revenio’s EPS estimate?
How many shares outstanding does Revenio have?
What happened to Revenio’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Revenio?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Revenio
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Probes that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used for measuring IOP on animal patients by general veterinary practitioners, veterinary ophthalmologists and other veterinary medical personnel. It also provides imaging devices comprising iCare EIDON, a device with confocal retinal imaging; iCare DRSplus, a device for pupil imaging; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images. In addition, the company offers iCare ILLUME, a screening software that helps to detect the early signs of diabetic retinopathy, age-related macular degeneration, and glaucoma using artificial intelligence; iCare CLINIC cloud software to store long-term IOP data; and Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities. Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland.
- Sector
- General
- Industry
- Medical - Devices
- CEO
- Jouni Erik Toijala
- Employees
- 765
- Website
- www.reveniogroup.fi
- Address
- Härkähaankuja 7, Vantaa, UU, 01730, FI
Revenio (0KFH) Earnings & Revenues
0KFH Earnings Call
Earnings Call SentimentPositive
The call was broadly positive, with strong reported growth from the enlarged company, a more than 30% increase in adjusted EBITDA in absolute terms, positive operating cash flow, an oversubscribed rights issue, faster-than-planned integration progress, and clear commercial and product initiatives. These positives were tempered by flat organic growth, APAC weakness, temporary U.S. sales pressure from the reorganization, significant gross-margin dilution, continued component-cost pressure, a reduced top end of sales guidance, limited cross-selling revenue to date, and the delayed ILLUME approval timeline. Overall, the highlights significantly outweighed the lowlights.
View all GB:0KFH earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 2 | 15 |
| Technical Analysis | 5 | 2 | 3 |
| Moving Averages | 0 | 0 | 12 |









